Trial Profile

Research into the safety of a new agent (NRG5051) in healthy adults and patients with Parkinson's disease or ALS

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 19 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NRG 5051 (Primary)
Indications Amyotrophic lateral sclerosis; Neurodegenerative disorders; Parkinson's disease
Focus Adverse reactions; First in man; Pharmacodynamics
Sponsors NRG Therapeutics

08 Jan 2026 According to a NRG Therapeutics media release, trial is being conducted at the Centre for Human Drug Research (CHDR) in Leiden, The Netherlands. The clinical trial is expected to readout by the end of 2026 and will inform dose selection in future studies in ALS/MND and Parkinson's patients.
08 Jan 2026 According to a NRG Therapeutics media release, the first participants have been dosed in its first-in-human Phase 1 clinical trial.
01 Dec 2025 Status changed from planning to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com